SIBO Treatment Protocol Guide

The complete reference for FM practitioners — from breath testing and gas pattern interpretation to antibiotic and herbal protocols, dietary support, root cause identification, and relapse prevention.

If you treat functional gut disorders, SIBO is in your clinic every week. The diagnosis gets missed for years in many patients — they cycle through IBS diagnoses, elimination diets, and antidepressants before someone runs a breath test. This guide covers the full clinical picture: how to confirm the diagnosis, which SIBO treatment protocol matches which gas pattern, how to use low FODMAP as a tool (not a lifestyle), and — critically — how to prevent the relapse that erases months of progress.

Bookmark it. Come back when a case gets complicated.

---

Table of Contents

1. What is SIBO? Types and Clinical Presentation
2. SIBO Breath Testing: How to Interpret Results
3. Hydrogen-Dominant SIBO: Rifaximin and Herbal Protocols
4. Methane-Dominant SIBO (IMO): Different Bug, Different Protocol
5. Hydrogen Sulfide SIBO: The Emerging Third Pattern
6. Mixed Patterns: When Two or Three Gases Are Elevated
7. Low FODMAP Diet: The Right Role in SIBO Treatment
8. Root Causes: What Drives SIBO and Why It Returns
9. Prokinetics and Maintenance: Preventing SIBO Relapse
10. Treatment Decision Framework: Building the Protocol
11. Case Studies
12. FAQ

---

1. What is SIBO?

Small intestinal bacterial overgrowth is defined by an abnormal increase in the number or type of bacteria in the small intestine — a zone of the GI tract that should carry relatively low bacterial counts (under 10³ CFU/mL) compared to the colon (10¹¹ CFU/mL). When bacteria colonize the small intestine in excess, they ferment carbohydrates before full absorption can occur, producing gases that drive the classic cluster: bloating that starts within an hour of eating, abdominal distension that worsens through the day, altered bowel patterns, and often significant fatigue that gets written off as something else.

In practice, when I see a patient who's been told they have IBS-D or IBS-C for years, who had a bad GI infection at some clear point in their history, and who's never been worked up further — SIBO is high on the differential until proven otherwise. The overlap isn't coincidental; it's mechanistic.

Three Types of SIBO

The three-type framework reflects the predominant gas produced by the microbial community involved:

Type	Gas Produced	Predominant Organisms	Primary Symptoms
Hydrogen-dominant	H₂	Streptococcus, E. coli, Klebsiella, Bacteroides	Bloating, diarrhea-predominant, gas
Methane-dominant (IMO)	CH₄	Methanobrevibacter smithii (archaea, not bacteria)	Constipation-predominant, severe bloating, slow transit
Hydrogen sulfide	H₂S	Sulfate-reducing bacteria (Desulfovibrio)	Diarrhea, sulfur-smelling gas, abdominal pain

Clinical note: Methane-dominant SIBO is now more accurately called Intestinal Methanogen Overgrowth (IMO) — methanogens are archaea, not bacteria, and can exist throughout the gut, not exclusively the small intestine. The distinction isn't academic; it drives protocol selection entirely.

Why SIBO Mimics IBS

SIBO accounts for a substantial subset of IBS diagnoses — estimates range from 30–85% of IBS-D cases testing positive on breath testing, with variance depending on methodology and diagnostic cutoffs. The overlap is mechanistic: the same dysregulated motility and carbohydrate fermentation that produces SIBO symptoms satisfies Rome IV IBS criteria. Practitioners who treat the SIBO routinely resolve the IBS. That is the correct order of operations.

---

2. SIBO Breath Testing: How to Interpret Results

Breath testing is the primary non-invasive diagnostic tool for SIBO. It measures exhaled H₂ and CH₄ following a fermentable substrate challenge — either lactulose (non-absorbable, tests the whole small bowel) or glucose (absorbable, tests only the proximal small bowel). Both substrates have legitimate uses depending on the clinical question.

Small intestinal bacterial overgrowth: the small bowel is the site of pathological bacterial colonization. Bacterial counts here should be <10³ CFU/mL; overgrowth occurs when this threshold is exceeded.

The Cutoffs

Gas	North American Consensus Cutoff	Pattern
Hydrogen (H₂)	≥20 ppm rise above baseline within 90 minutes	Hydrogen-dominant SIBO
Methane (CH₄)	≥10 ppm at any point in the test	IMO (methane-dominant)
Hydrogen sulfide (H₂S)	Detected at any level (requires dedicated H₂S sensor)	H₂S-SIBO — standard tests don't measure this
Flat-line pattern	H₂ and CH₄ both near-zero throughout	May indicate H₂S (H₂ consumed by sulfate-reducers); also consider poor prep compliance

SIBO breath test interpretation: three gas patterns over 180 minutes. Positive hydrogen SIBO (blue), IMO/methane pattern (green), and H₂S-suspect flat line (gray).

Lactulose vs. Glucose Substrate

Factor	Lactulose	Glucose
What it tests	Whole small bowel transit	Proximal small bowel only
False positives	Higher (colonic bacteria can cause late peak)	Lower
False negatives	Lower	Higher (misses distal SIBO)
Most common in practice	Yes	Yes (used for proximal confirmation)

How to read the lactulose breath test: A hydrogen rise ≥20 ppm within 90 minutes is positive for hydrogen SIBO. A rise after 90–120 minutes may represent colonic fermentation — treat it as a borderline or false positive unless the clinical picture strongly supports SIBO. Methane ≥10 ppm at any point is positive for IMO regardless of timing.

The Flat-Line Problem

A test where both H₂ and CH₄ run near-zero throughout is not automatically negative. Sulfate-reducing bacteria consume hydrogen as an electron donor in the H₂S production pathway — so a flat H₂ reading combined with ongoing gut symptoms should raise suspicion for hydrogen sulfide SIBO. Standard two-gas breath tests cannot measure H₂S. Diagnosis requires clinical pattern recognition (sulfur-smelling gas, diarrhea, flat-line test) and either specialized H₂S breath testing where available or empirical treatment trial.

See also: SIBO Diet and Breath Test Interpretation — detailed guide to substrate selection, prep protocols, and result interpretation pitfalls.

---

3. Hydrogen-Dominant SIBO: Rifaximin and Herbal Protocols

Hydrogen-dominant SIBO is the most common presentation and the most studied. You have two well-supported treatment pathways.

SIBO Treatment: Rifaximin Protocol

Standard rifaximin dosing for SIBO treatment: 550 mg three times daily for 14 days.

Rifaximin is a non-absorbable antibiotic — it acts entirely within the gut lumen, which gives it a markedly better safety profile relative to systemic antibiotics and does not disrupt the gut microbiome to the same degree as oral systemic agents. Patients tolerate it well; GI side effects are modest.

Efficacy data: Barkin et al. (PMID 31333225) demonstrated approximately 47% improvement for hydrogen-only SIBO with a single rifaximin course, and approximately 80% for the combined hydrogen + methane pattern. That 47% figure is worth sitting with. More than half of hydrogen-dominant patients don't achieve full eradication on a single 14-day course. The clinical question becomes: what do you do with the other 53%? Options include a second rifaximin course with herbal augmentation (bismuth, berberine), switching mechanism entirely to a herbal SIBO protocol for round two, or escalating to dual-antibiotic therapy.

Herbal Protocol for Hydrogen SIBO

Herbal SIBO protocols have earned meaningful evidence support. Chedid et al. (PMID 24891990) demonstrated that a herbal antimicrobial protocol including berberine and oil of oregano produced outcomes statistically comparable to rifaximin — which matters both for patients who can't access rifaximin at $1,500+ per course and for practitioners looking to switch mechanisms after a failed first round.

Rifaximin (14 days, 550 mg TID, ~47% H₂-only eradication, Rx required, ~$1,500) vs. herbal protocol (6 weeks, berberine + oregano, comparable efficacy, OTC, ~$40–80).

Core herbal combinations for hydrogen-dominant SIBO:

Herb	Dose	Mechanism
Berberine	500 mg 2–3× daily	Broad-spectrum antimicrobial; inhibits bacterial biofilms
Oil of oregano	500 mg 2× daily	Carvacrol/thymol — antimicrobial against E. coli, Klebsiella
Neem	300 mg 2× daily	Synergistic with berberine; anti-biofilm properties
Allicin	450 mg 2–3× daily	Garlic-derived; active against gram-negative organisms

Duration: 6 weeks, versus 14 days for rifaximin. Some practitioners rotate herb combinations at week 3 to reduce adaptive resistance — a reasonable strategy without strong controlled data behind it, but mechanistically sound.

Who benefits most from the herbal SIBO protocol:

• Patients who relapsed after rifaximin (switching mechanism is clinically sensible)
• Patients who cannot afford rifaximin without insurance coverage
• Patients who have failed multiple antibiotic courses and want a genuinely different approach

See also: SIBO Treatment Protocol: Antibiotic vs. Herbal Protocols — full comparison table, rifaximin augmentation strategies, and herbal selection by gas pattern.

---

4. Methane-Dominant SIBO (IMO): Different Bug, Different Protocol

Methane-dominant presentation — classified as Intestinal Methanogen Overgrowth (IMO) — requires a completely different treatment approach. Methanobrevibacter smithii, the primary methane-producing archaeon, is not a bacterium. Rifaximin alone does not cover it.

Why IMO Is Harder to Treat

Methanogens are archaea — they have a different cell wall structure than bacteria, making most standard antibiotics ineffective against them as a monotherapy. They also slow intestinal transit directly: methane gas decreases small bowel contractility, which explains why IMO presents with constipation-dominant symptoms rather than diarrhea. You're dealing with both an overgrowth and the motility consequence of that overgrowth simultaneously.

In practice, when I see a patient with severe bloating, constipation, and a methane level ≥10 ppm on their breath test, I know upfront that this will take longer than hydrogen-dominant SIBO. Set patient expectations accordingly.

IMO Treatment Protocols

Option 1: Dual antibiotic (gold standard)

Antibiotic	Dose	Duration
Rifaximin	550 mg TID	14 days
Neomycin	500 mg BID	14 days

The combination is necessary because neomycin targets the archaea while rifaximin addresses the co-existing hydrogen-producing bacteria that feed the methanogens. Without the hydrogen substrate, M. smithii can't sustain itself — which is why the dual approach outperforms monotherapy. Neomycin carries more GI side effect risk than rifaximin; counsel patients proactively on potential nausea and diarrhea during the course.

Option 2: Rifaximin + Allicin (herbal alternative)

Some practitioners replace neomycin with high-dose allicin garlic extract as the methane-targeting agent. This is less studied in controlled trials but is reported in clinical practice as effective for mild-to-moderate IMO, and is a reasonable alternative for patients who cannot tolerate neomycin.

Option 3: Herbal combination for IMO

• Allicin 450 mg 3× daily (methane-targeting)
• Berberine 500 mg 2× daily (hydrogen bacteria component)
• Atrantil (peppermint, quebracho, conker tree extract) — some evidence for methane reduction; better tolerated than most alternatives

Prokinetics Are Critical in IMO

Because methane gas itself slows motility, IMO patients are at distinctly high relapse risk without aggressive prokinetic support post-treatment. Start prokinetics concurrent with antimicrobial treatment — don't wait until you've cleared the overgrowth — and continue for at least 3 months after confirmed eradication.

---

5. Hydrogen Sulfide SIBO: The Emerging Third Pattern

H₂S-SIBO is produced by sulfate-reducing bacteria (SRB) — primarily Desulfovibrio species — that use hydrogen as an electron donor to reduce sulfate into hydrogen sulfide gas.

Clinical Profile

The presenting picture is fairly characteristic when you know what to look for: watery or loose diarrhea, a notably sulfurous or rotten-egg quality to the flatus that patients are often embarrassed to describe, abdominal cramping, and significant fatigue that tends to be disproportionate to the GI complaints. The breath test will look negative — H₂ near zero, CH₄ near zero — because the SRB are consuming the hydrogen before it can be exhaled and measured. Standard two-gas breath tests cannot detect H₂S.

This is a diagnosis-by-pattern situation. A flat-line test in a symptomatic patient with characteristic sulfur gas and diarrhea warrants an H₂S treatment trial even without confirmatory testing.

Treatment Approach

H₂S-SIBO treatment protocols are still evolving — acknowledge that to your patient. The approach with the most clinical support:

Rifaximin + bismuth subsalicylate:

• Rifaximin 550 mg TID × 14 days
• Bismuth subsalicylate 262–524 mg 4× daily × 14 days (bismuth binds sulfide, reducing H₂S availability to SRB)

Dietary modification: Low-sulfur diet during treatment reduces the substrate load available to sulfate-reducing bacteria. Temporarily reduce sulfur-rich foods — eggs, red meat, cruciferous vegetables, garlic, onion — for the duration of treatment. This is a short-term adjunct only; do not frame it as a permanent restriction.

---

6. Mixed Patterns: When Two or Three Gases Are Elevated

Mixed SIBO — elevated H₂ and CH₄ simultaneously — is common in clinical practice and associated with more severe symptoms and a harder clinical course than single-gas presentations. Somewhat counterintuitively, Barkin et al. (PMID 31333225) showed approximately 80% improvement with rifaximin monotherapy in combined hydrogen + methane patterns — better than hydrogen-only cases. This may reflect a more rifaximin-responsive microbial ecosystem in mixed presentations, though the mechanism isn't fully characterized.

Protocol for mixed SIBO:

Approach	Protocol
First-line	Rifaximin 550 mg TID × 14 days
If methane-dominant within mixed	Add neomycin 500 mg BID × 14 days
Herbal alternative	Berberine 500 mg BID + allicin 450 mg TID × 6 weeks

Acknowledge the controversy here: there is no universal consensus on whether all mixed patterns need dual therapy or whether rifaximin monotherapy should be trialed first. I lean toward trialing monotherapy first for mild-to-moderate mixed cases and escalating to dual therapy on failed response — but practitioners who start with dual therapy in all methane-positive patients have defensible reasoning.

---

7. Low FODMAP Diet: The Right Role in SIBO Treatment

Low FODMAP is one of the most commonly misapplied tools in SIBO management. It is not a treatment for SIBO. It is a symptom management tool — one that provides genuine adjunctive support during active antimicrobial therapy, but is actively counterproductive when applied indefinitely.

What Low FODMAP Does

During active antimicrobial treatment, restricting fermentable oligosaccharides, disaccharides, monosaccharides, and polyols reduces the substrate available to overgrown bacteria. This accomplishes two things:

1. Reduces symptom burden during treatment — less bloating, gas, and diarrhea while the antimicrobials work
2. May enhance antimicrobial efficacy by reducing bacterial metabolic activity and fermentative pressure

What Low FODMAP Does NOT Do

It does not eradicate bacteria. Long-term low FODMAP alters the colonic microbiome — specifically, it reduces prebiotic fiber feeding to beneficial organisms like Bifidobacterium (Staudacher et al., PMID 28625832; Halmos et al. meta-analysis, PMID 35728042). Patients who maintain strict low FODMAP indefinitely are managing symptoms, not addressing root cause. When I see a patient who has been on strict low FODMAP for 12+ months with no reintroduction attempt, that is a flag that the underlying SIBO was never properly treated.

The Practical SIBO Low FODMAP Framework

Phase	Dietary Approach
Weeks 1–4 (active antimicrobial)	Strict low FODMAP — reduce bacterial substrate load
Weeks 5–6 (tapering treatment)	Begin systematic FODMAP reintroduction (one group per week)
Post-treatment	Individualized tolerance-based diet — not permanent restriction
Long-term	Normal varied diet with mindful avoidance of confirmed personal triggers

The goal of the reintroduction phase is to identify specific personal triggers, not to establish permanent restriction. Every food group that can be safely reintroduced should be — for microbiome health, dietary adequacy, and quality of life.

---

8. Root Causes: What Drives SIBO and Why It Returns

This is the section that separates successful SIBO management from the revolving door of recurrence. Treating the bacterial overgrowth without addressing the underlying condition that allowed it to develop is — at best — a 3-month fix.

This is also where HANS pays dividends: tracking root cause workup across visits — thyroid panels, anti-CdtB results, PPI taper progress, motility history — requires structured longitudinal documentation that a general-purpose EMR wasn't designed for. HANS for FM Practitioners keeps all of it organized and visible.

The Migrating Motor Complex: The Central Mechanism

The most important root cause to understand is MMC dysfunction. The migrating motor complex is a cyclical electrical sweep that moves through the small intestine during fasting — typically every 90–120 minutes between meals. Its function is to act as a housekeeper wave, sweeping residual food particles and bacteria from the small bowel into the colon before they can accumulate.

When the MMC is impaired, bacteria that should be cleared downstream stay put and proliferate. Common causes:

• Chronic stress — stress hormones directly inhibit interstitial cells of Cajal that drive the MMC
• Post-infectious injury — Campylobacter, Giardia, and similar enteropathogens produce anti-CdtB antibodies that cross-react with vinculin, impairing the neural connections driving MMC activity (Pimentel et al., PMID 25424202)
• Opioid medications — suppress motility globally
• Hypothyroidism — slows motility at all levels
• Gastroparesis

Common Root Causes

Root Cause	Mechanism	Clinical Signal
MMC dysfunction	Lost housekeeping sweep	History of GI infection before onset; slow transit
PPI / acid suppression	Reduced gastric acid → less bacterial killing in proximal GI	Current PPI use; H. pylori treatment history
Structural factors	Blind loops, adhesions, ileocecal valve incompetence	Surgical history, Crohn's, pelvic adhesions
Hypothyroidism	Slows motility globally	Check TSH, Free T3 in constipation-dominant SIBO
Diabetes / autonomic neuropathy	Impairs gut motility	Peripheral neuropathy, gastroparesis history
Post-infectious SIBO (PI-SIBO)	Anti-vinculin autoimmunity impairing enteric nervous system	Clear onset after acute GI illness
Hypochlorhydria	Allows bacterial colonization through proximal GI	Antacid use, H. pylori history, aging

Post-Infectious SIBO: A Special Case

Post-infectious SIBO has a distinct immunological mechanism that makes it both underdiagnosed and treatment-resistant without targeted intervention. Campylobacter jejuni produces cytolethal distending toxin B (CdtB). The immune response generates anti-CdtB antibodies that cross-react with vinculin — a protein critical to enteric neuromuscular junction function. The result: molecular mimicry-driven autoimmune impairment of the MMC, persisting long after the original infection resolves (Pimentel et al., PMID 25424202).

Testing: Anti-CdtB and anti-vinculin antibodies via ibs-smart (Commonwealth Diagnostics / Pimentel lab). Positive in a patient with clear post-infectious onset supports PI-SIBO and alters the treatment plan toward long-term prokinetics and immune modulation. Antibody subtypes differ by IBS phenotype — IBS-D and IBS-M show higher positivity rates than IBS-C (Rezaie et al., PMID 28451914).

Treatment implication: Standard SIBO treatment protocols clear the overgrowth — but relapse is highly likely without persistent prokinetic therapy addressing the underlying motility deficit. This is not a one-course case.

---

9. Prokinetics and Maintenance: Preventing SIBO Relapse

The most important question in SIBO management is not "how do I clear it?" — it's "how do I keep it from coming back?" This is where most SIBO management fails.

Why Relapse Happens

After a successful treatment course — negative repeat breath test, symptom resolution — bacteria return unless the condition that permitted overgrowth is corrected. Without prokinetic maintenance:

• The MMC remains impaired
• Bacteria recolonize the small bowel within weeks to months
• Many patients relapse within 3–6 months of successful eradication, and come back frustrated that "SIBO came back again"

Prokinetic Options

Clinical reference: prokinetic agents for SIBO relapse prevention. Ginger, Iberogast, low-dose erythromycin, LDN, prucalopride, domperidone — dosing and indications.

Agent	Dose	Notes
Ginger	500 mg 4× daily (between meals + before bed)	OTC; stimulates MMC; best starting point for most patients
Low-dose erythromycin	50–75 mg before bed	Motilin receptor agonist; most-studied Rx prokinetic for MMC
Low-dose naltrexone (LDN)	1.5–4.5 mg before bed	Modulates gut motility + immune function; valuable in PI-SIBO
Iberogast (STW-5)	20 drops 3× daily	Prokinetic + antispasmodic herbal blend; strong safety profile
Prucalopride	1–2 mg daily	5-HT4 agonist; FDA-approved for chronic idiopathic constipation; useful in IMO
Domperidone	10 mg before meals	Dopamine antagonist; promotes upper GI motility; available outside US

Clinical standard: Ginger 500 mg QID is the right starting point for most patients — well-tolerated, accessible, and evidence-supported for MMC stimulation. Escalate to prescription prokinetics (low-dose erythromycin or LDN) for confirmed PI-SIBO, IMO, or documented refractory MMC dysfunction.

Meal Spacing: The Free Intervention

The MMC only activates during fasting. Continuous eating — grazing, snacking between meals, the "six small meals a day" advice that still persists — suppresses the housekeeping sweep and allows bacterial accumulation even with normal MMC function.

Practical recommendation:

• Minimum 4-hour gaps between eating episodes — no snacks
• 12–14 hour overnight fast
• Last meal at least 3 hours before bed

This single behavioral change costs nothing and reduces relapse risk meaningfully. I explain it to every SIBO patient: "Your gut needs downtime to clean itself. Every time you eat, you reset that clock."

Root Cause Correction — Non-Negotiable

Root Cause	Target Intervention
PPI dependency	Taper PPIs when clinically safe; transition to betaine HCl + pepsin
Hypothyroidism	Optimize thyroid with Free T3 target, not just TSH normalization
Post-infectious autoimmunity	Long-term prokinetics; consider LDN for immune modulation
Hypochlorhydria	Betaine HCl 650–1,000 mg with protein-containing meals
Structural causes	Surgical consultation when indicated (adhesions, blind loops)
Stress / MMC suppression	Vagal tone training (HRV biofeedback, breathwork), sleep optimization

---

10. Treatment Decision Framework: Building the Protocol

SIBO treatment selection by gas pattern: four clinical pathways from breath test result to antimicrobial protocol.

Step 1: Confirm the Gas Pattern

Read the breath test. Identify the predominant gas:

• H₂ ≥20 ppm rise within 90 min → hydrogen-dominant
• CH₄ ≥10 ppm at any point → IMO
• Both elevated → mixed
• Flat line + sulfur symptoms → H₂S (empirical treatment warranted)

Step 2: Select the Antimicrobial Protocol

Pattern	First-Line	Alternative
Hydrogen-dominant	Rifaximin 550 mg TID × 14 days	Berberine 500 mg BID + oregano 500 mg BID × 6 weeks
IMO (methane)	Rifaximin 550 mg TID + neomycin 500 mg BID × 14 days	Rifaximin + allicin 450 mg TID × 14 days
Mixed (H₂ + CH₄)	Rifaximin 550 mg TID × 14 days ± neomycin if methane-dominant	Berberine + allicin × 6 weeks
H₂S	Rifaximin 550 mg TID + bismuth subsalicylate 262–524 mg QID × 14 days	Empirical; guide by symptom response

Step 3: Add Dietary Support

Weeks 1–4: strict low FODMAP to reduce bacterial substrate. Post-treatment: systematic FODMAP reintroduction. Long-term: individualized. Do not prescribe permanent restriction.

Step 4: Begin Prokinetic Concurrently

Ginger 500 mg QID or Iberogast 20 drops TID — start with antimicrobials, not after. Escalate to Rx prokinetics for IMO, PI-SIBO, or cases with documented MMC dysfunction.

Step 5: Address Root Causes Simultaneously

Taper PPIs, optimize thyroid, implement meal spacing, manage stress, check anti-CdtB/vinculin if post-infectious history.

Step 6: Retest at 4–8 Weeks Post-Treatment

Repeat breath test. Negative + symptom resolution = success, continue prokinetics for 3–6 months. Positive retest or persistent symptoms = second-line protocol (switch mechanism, escalate to dual therapy, consider elemental diet).

---

11. Case Studies

Case 1: 34F — Hydrogen-Dominant SIBO, Post-Infectious, Partial Rifaximin Response

Presentation: 34-year-old woman, 2 years of progressive bloating and diarrhea-predominant gut symptoms following a clear-cut episode of Campylobacter gastroenteritis during international travel. Had received one prior rifaximin course (550 mg TID × 14 days) from a GI colleague — good response for approximately 6 weeks, then full relapse. Presenting fatigued, frustrated, and convinced she had IBS.

Workup: Lactulose breath test — hydrogen rise of 45 ppm at 90 minutes, methane negative. Anti-CdtB antibody: positive. Anti-vinculin: positive. Diagnosis: post-infectious hydrogen-dominant SIBO with underlying PI-SIBO autoimmune mechanism.

What the first course missed: Rifaximin worked on the bacterial overgrowth, but the MMC damage from the Campylobacter-induced autoimmunity was never addressed. No prokinetic was started. No root cause work was done. The overgrowth cleared; the conditions for recurrence were left entirely intact.

Protocol:

1. Rifaximin 550 mg TID × 14 days — second course
2. Berberine 500 mg BID weeks 2–6 (herbal overlap post-rifaximin to prevent immediate re-seeding during the vulnerable post-antibiotic window)
3. Low FODMAP weeks 1–4; systematic reintroduction weeks 5–6
4. Ginger 500 mg QID — started week 1, continued 6 months
5. Meal spacing: 4+ hour gaps, 12-hour overnight fast — explained in detail
6. LDN 2 mg at bedtime — started week 6 for PI-SIBO autoimmune component

Outcome: Bloating and diarrhea resolved by week 3. Breath test negative at 8-week retest. At 6-month follow-up: no relapse, tolerating a near-normal diet, energy substantially improved.

Clinical lesson: The PI-SIBO mechanism is the key variable here. A positive anti-CdtB in a patient with clear post-infectious onset reframes the entire case. The overgrowth is a symptom of impaired MMC function, not the root problem. Address the autoimmune mechanism — with long-term prokinetics and LDN — and the relapse rate drops dramatically. Without it, you're clearing bacteria in a body that has no functional capacity to keep them cleared.

---

Case 2: 58M — Constipation-Dominant IMO, Hypothyroidism, PPI Dependency

Presentation: 58-year-old man presenting with severe abdominal distension, constipation (2–3 stools per week for years), unexplained 20-lb weight gain over 18 months, and a sulfur quality to morning breath he'd never mentioned to anyone. GI had diagnosed IBS-C and managed him with polyethylene glycol. Prior to this visit, he'd been on a PPI for 3 years for GERD.

Workup: Lactulose breath test — methane 28 ppm at baseline, rising to 42 ppm at 60 minutes. Hydrogen: negative throughout. Thyroid panel: TSH 4.8 mIU/L, Free T3 2.1 pg/mL (low-normal, below functional target). Diagnosis: methane-dominant IMO with hypothyroidism and PPI-related hypochlorhydria as contributing root causes.

What the prior workup missed: No one had run a breath test. No one had checked a full thyroid panel including Free T3 — TSH in the "normal" range was assumed adequate. The PPI was continued indefinitely. All three root causes were present and untreated; the IMO was the predictable downstream consequence.

Protocol:

1. Rifaximin 550 mg TID + neomycin 500 mg BID × 14 days (IMO dual protocol)
2. Low FODMAP weeks 1–4; gradual reintroduction starting week 5
3. Prucalopride 1 mg daily — started concurrent with antimicrobials; IMO-driven slow transit requires prokinetic support from day one
4. Thyroid optimization: switch to desiccated thyroid, titrate to target Free T3 3.0–3.5 pg/mL
5. PPI taper: structured 6-week taper with transition to betaine HCl 750 mg with meals and dietary GERD management

Outcome: Bowel frequency normalized to daily by week 4 — a significant quality-of-life change for a patient who hadn't had a normal stool pattern in years. Methane breath test at 6-week retest: 6 ppm (negative). GERD symptoms resolved with PPI taper and HCl support, which he found surprising. Weight loss of 8 lbs at 3-month follow-up without intentional dietary restriction.

Clinical lesson: IMO in a hypothyroid patient on a PPI is a setup for indefinite recurrence if you treat only the overgrowth. Thyroid optimization restores motility at a systemic level; PPI taper restores proximal GI bacterial killing. Both interventions are necessary to change the terrain. The weight loss and GERD resolution were downstream benefits of addressing root cause — not separate problems requiring separate treatments.

---

12. FAQ

Q: Should I always confirm SIBO with a breath test before treating?

A: Not necessarily. For patients with a compelling clinical picture — especially post-infectious onset, clear IBS-C or IBS-D phenotype, history of confirmed food poisoning — empirical treatment is clinically reasonable when testing is unavailable or impractical. The breath test becomes most valuable when: (a) the diagnosis is uncertain, (b) you want to identify which gas pattern to target your protocol, (c) you're evaluating post-treatment response objectively, or (d) a patient has had multiple failed courses and you need to reestablish what you're actually treating. For complex or recurrent cases, I consider a breath test non-negotiable. For a clear-cut first presentation, empirical trial is defensible.

---

Q: How long should I wait between treatment courses?

A: Allow at least 2 weeks between courses to assess symptom response and permit post-treatment microbiome changes to stabilize. For repeat breath testing, wait 4–8 weeks post-treatment — gastric acid, motility, and flora need time to re-equilibrate after antibiotics, and testing too soon significantly increases false-negative rates. A negative breath test at 2 weeks may not reflect the true bacterial burden; at 6–8 weeks it's a more reliable signal.

---

Q: Can probiotics make SIBO worse?

A: Yes — and this is an underappreciated clinical problem. Some patients with SIBO experience worsening bloating and symptoms with probiotic supplementation, particularly Lactobacillus-dominant products, because adding live organisms to an already overpopulated small intestine exacerbates fermentation. General rule: Hold probiotics during active antimicrobial treatment. Post-treatment, soil-based organisms (Bacillus coagulans, Bacillus subtilis) or Saccharomyces boulardii (a yeast, not affected by bacterial dysbiosis) are better tolerated than traditional Lactobacillus/Bifidobacterium products in the immediate post-SIBO recovery period. Reintroduce conventional probiotics gradually once the small bowel has had time to reestablish normal flora distribution.

---

Q: What's the role of the elemental diet in SIBO?

A: The elemental diet — pre-digested amino acids, simple carbohydrates, and fat with no intact proteins or fiber — achieves approximately 80% normalization of the lactulose breath test when used for 14 days (Pimentel et al., PMID 14992438), comparable to or exceeding antibiotic protocols. The mechanism: the formula absorbs almost entirely in the proximal small intestine, leaving essentially no substrate for bacterial fermentation distally. It effectively starves the overgrowth. The limitation is tolerability — taste, cost, and the social burden of 2–3 weeks on a liquid-only formula make adherence difficult. Best reserved for: patients with true antibiotic intolerance, severe allergy contraindications, or treatment-refractory cases where two or more antibiotic courses have failed without sustained eradication.

---

Q: Is SIBO related to histamine intolerance?

A: Yes — there is a clinically meaningful, mechanistic overlap. SIBO impairs small intestinal absorptive capacity, including diamine oxidase (DAO) enzyme activity. DAO is the primary enzyme degrading dietary histamine in the gut. When SIBO reduces DAO activity, histamine from aged cheeses, wine, fermented products, and cured meats can accumulate — producing histamine intolerance symptoms including flushing, urticaria, headache, and GI distress that are often attributed to food allergy or sensitivity. Treating the underlying SIBO often resolves or significantly improves histamine intolerance without permanent dietary restriction — which is the correct approach, since indefinite low-histamine dieting is managing a consequence rather than treating a cause.

---

Q: Can SIBO cause nutrient deficiencies?

A: Yes, and this is often the mechanism behind fatigue in SIBO patients. Bacterial overgrowth in the small intestine can:

• Deplete fat-soluble vitamins (A, D, E, K) via impaired fat digestion from bacterial bile acid deconjugation
• Deplete B12 — bacteria either compete for B12 or consume it directly
• Cause iron deficiency — inflammatory response in the small intestinal mucosa impairs iron absorption
• Deplete folate — bacterial competition or direct consumption

Clinical tip: In any SIBO patient with unexplained fatigue or neurological symptoms, check B12, ferritin, 25-OH vitamin D, and a fat-soluble vitamin panel. Repletion should begin concurrently with SIBO treatment — don't wait for full eradication, because deficiencies that developed over months don't resolve in weeks even after the bacteria are cleared.

---

Citations

• PMID 31333225 — Barkin JA, et al. (2019). Preferential usage of rifaximin for the treatment of hydrogen-positive small intestinal bacterial overgrowth. Rev Gastroenterol Peru. https://pubmed.ncbi.nlm.nih.gov/31333225/
• PMID 10235214 — Bouhnik Y, et al. (1999). Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol. https://pubmed.ncbi.nlm.nih.gov/10235214/
• PMID 24891990 — Chedid V, et al. (2014). Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. https://pubmed.ncbi.nlm.nih.gov/24891990/ (PMC4030608)
• PMID 25424202 — Pimentel M, et al. (2015). Autoimmunity links vinculin to the pathophysiology of chronic functional bowel changes following Campylobacter jejuni infection in a rat model. Dig Dis Sci. https://pubmed.ncbi.nlm.nih.gov/25424202/
• PMID 28451914 — Rezaie A, et al. (2017). Assessment of anti-vinculin and anti-cytolethal distending toxin B antibodies in subtypes of irritable bowel syndrome. Dig Dis Sci. https://pubmed.ncbi.nlm.nih.gov/28451914/
• PMID 14992438 — Pimentel M, et al. (2004). A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Dig Dis Sci. https://pubmed.ncbi.nlm.nih.gov/14992438/
• PMID 28625832 — Staudacher HM, et al. (2017). A diet low in FODMAPs reduces symptoms in patients with irritable bowel syndrome and a probiotic restores Bifidobacterium species: a randomized controlled trial. Gastroenterology. https://pubmed.ncbi.nlm.nih.gov/28625832/
• PMID 35728042 — Dolan R, et al. (2022). Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: a systematic review with meta-analysis. Eur J Nutr. https://pubmed.ncbi.nlm.nih.gov/35728042/
• NCBI Bookshelf NBK546634 — SIBO treatment protocols, antibiotic options, dosing summary. https://www.ncbi.nlm.nih.gov/books/NBK546634/

---

Ready to stop rebuilding your SIBO protocol from scratch every visit?

SIBO cases generate dense documentation — breath test results, multi-phase protocols, repeat testing timelines, root cause tracking across multiple systems. Keeping all of that organized across visits is genuinely difficult in a general-purpose EMR not built for this kind of layered clinical reasoning.

HANS is built for exactly this. The AI-native EMR for functional medicine tracks your SIBO protocols, generates structured clinical notes, and keeps root cause workup — thyroid, anti-CdtB, motility, dietary phase — organized and visible across visits. No more digging through visit notes to remember where you left off on the PPI taper.

Already using Rupa Health for breath test ordering? HANS integrates with Rupa lab results and automatically populates protocol templates for SIBO, IMO, and H₂S patterns — so your documentation keeps pace with your clinical thinking.

See how HANS supports complex GI cases → HANS for FM Practitioners

---